Anke Baum

3.7k total citations · 2 hit papers
32 papers, 2.8k citations indexed

About

Anke Baum is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anke Baum has authored 32 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anke Baum's work include Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers) and Multiple Myeloma Research and Treatments (6 papers). Anke Baum is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers) and Multiple Myeloma Research and Treatments (6 papers). Anke Baum collaborates with scholars based in Austria, Germany and United States. Anke Baum's co-authors include Wolfgang J. Rettig, Pilar Garin‐Chesa, Günther R. Adolf, Flavio Solca, Frank Himmelsbach, Jens Quant, Martin Steegmaier, Matthias Hoffmann, Matthias Grauert and Heidi Greulich and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Anke Baum

31 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

2008 1.2k citations Anke Baum, Frank Himmelsbach et al. Oncogene profile →
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

2007 691 citations Martin Steegmaier, Matthias Hoffmann et al. Current Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anke Baum Austria	14	1.6k	1.4k	978	666	260	32	2.8k
Danan Li United States	16	2.3k 1.4×	1.6k 1.1×	1.0k 1.0×	251 0.4×	236 0.9×	21	3.2k
Nicholas Kwiatkowski United States	31	3.2k 2.0×	1.5k 1.1×	599 0.6×	478 0.7×	273 1.1×	48	3.9k
Mathias Schmidt Germany	25	1.3k 0.8×	1.1k 0.7×	274 0.3×	451 0.7×	145 0.6×	59	2.2k
Ralf Brandt United States	18	1.9k 1.2×	2.5k 1.8×	1.1k 1.1×	329 0.5×	165 0.6×	27	4.0k
Flavio Solca Austria	26	1.8k 1.1×	2.3k 1.6×	2.0k 2.0×	217 0.3×	433 1.7×	85	3.8k
Kristen E. Mengwasser United States	7	1.5k 0.9×	1.1k 0.8×	1.1k 1.1×	151 0.2×	236 0.9×	8	2.4k
Ayana Sawai United States	9	2.7k 1.7×	1.1k 0.8×	539 0.6×	183 0.3×	145 0.6×	10	3.3k
George N. Naumov United States	22	1.9k 1.2×	2.3k 1.6×	1.3k 1.4×	291 0.4×	163 0.6×	37	4.0k
Jens Quant Austria	9	1.1k 0.7×	732 0.5×	562 0.6×	684 1.0×	79 0.3×	15	2.0k
Sheri L. Moores United States	22	1.7k 1.1×	762 0.5×	395 0.4×	705 1.1×	85 0.3×	31	3.2k

Countries citing papers authored by Anke Baum

Since Specialization

Citations

This map shows the geographic impact of Anke Baum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Baum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Baum more than expected).

Fields of papers citing papers by Anke Baum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke Baum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Baum. The network helps show where Anke Baum may publish in the future.

Co-authorship network of co-authors of Anke Baum

This figure shows the co-authorship network connecting the top 25 collaborators of Anke Baum. A scholar is included among the top collaborators of Anke Baum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke Baum. Anke Baum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, You Won, Jii Bum Lee, Min Hee Hong, et al.. (2024). Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clinical Cancer Research. 30(8). 1582–1594. 10 indexed citations

Wilding, Birgit, Martin Augsten, Anke Baum, et al.. (2024). 136 (PB124): Zongertinib (BI1810631), an irreversible HER2 TKI spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. European Journal of Cancer. 211. 114659–114659.

Tontsch-Grunt, Ulrike, Anke Baum, Hanny Musa, et al.. (2022). Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. British Journal of Cancer. 127(3). 577–586. 22 indexed citations

Hofmann, Irmgard, Anke Baum, Marco H. Hofmann, et al.. (2022). Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition. Journal of Pharmacology and Experimental Therapeutics. 384(3). 331–342. 9 indexed citations

Tontsch-Grunt, Ulrike, Dorothea Rudolph, Irene C. Waizenegger, et al.. (2018). Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Letters. 421. 112–120. 34 indexed citations

Gerlach, Daniel, Ulrike Tontsch-Grunt, Anke Baum, et al.. (2018). The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene. 37(20). 2687–2701. 66 indexed citations

Hilberg, Frank, Ulrike Tontsch-Grunt, Anke Baum, et al.. (2017). Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. Journal of Pharmacology and Experimental Therapeutics. 364(3). 494–503. 90 indexed citations

Waizenegger, Irene C., Anke Baum, Steffen Steurer, et al.. (2016). A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation. Molecular Cancer Therapeutics. 15(3). 354–365. 68 indexed citations

Tontsch-Grunt, Ulrike, Fabio Savarese, Anke Baum, et al.. (2016). Effects of the novel BET inhibitor BI 894999 on upregulation of HEXIM1 in cancer cells and on antitumor activity in xenograft tumor models.. Journal of Clinical Oncology. 34(15_suppl). 11574–11574. 1 indexed citations

10.

Young, Natalie, Jing Liu, Tatyana A. Grushko, et al.. (2015). Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Targeted Oncology. 10(4). 501–508. 20 indexed citations

11.

Rudolph, Dorothea, Martin Steegmaier, Matthias Hoffmann, et al.. (2009). BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity. Clinical Cancer Research. 15(9). 3094–3102. 322 indexed citations

12.

Rudolph, Dorothea, Martin Steegmaier, Matthias Grauert, et al.. (2008). 430 POSTER Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer. European Journal of Cancer Supplements. 6(12). 135–135. 5 indexed citations

13.

Baum, Anke, Pilar Garin‐Chesa, Ulrich Gürtler, Gerd Munzert, & Dorothea Rudolph. (2007). PD2-1-1: Efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in models of human non-small cell lung carcinoma. Journal of Thoracic Oncology. 2(8). S435–S436. 4 indexed citations

14.

Steegmaier, Martin, Matthias Hoffmann, Anke Baum, et al.. (2007). BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo. Current Biology. 17(4). 316–322. 691 indexed citations breakdown →

15.

Solca, Flavio, et al.. (2006). 567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents. European Journal of Cancer Supplements. 4(12). 172–172. 15 indexed citations

16.

Solca, Flavio, Anke Baum, Elke Langkopf, et al.. (2004). Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives. Journal of Pharmacology and Experimental Therapeutics. 311(2). 502–509. 39 indexed citations

17.

Stratowa, Christian, Anke Baum, M Castañón, et al.. (1999). A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity.. PubMed. 14(5). 393–402. 7 indexed citations

18.

Baum, Anke, Meike Mevissen, Kenji Kamino, U. Möhr, & Wolfgang Löscher. (1995). A histopathological study on alterations in DMBA-induced mammary carcinogenesis in rats with 50 Hz, 100 μT magnetic field exposure. Carcinogenesis. 16(1). 119–125. 79 indexed citations

19.

Baum, Anke, et al.. (1995). Lewis rats of the inbred strain LEW/Han: Life expectancy, spectrum and incidence of spontaneous neoplasms. Experimental and Toxicologic Pathology. 47(1). 11–18. 10 indexed citations

20.

Baum, Anke, Kenji Kamino, Woo‐Chan Son, & Heinrich Ernst. (1995). Lack of influence of diethylstilbestrol on induced pancreatic ductal carcinomas in Syrian hamsters. Experimental and Toxicologic Pathology. 47(2-3). 117–120. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact